Yellow fever (YF) vaccine is considered safe; however, severe illness and death following vaccination have been reported.
Yellow fever (YF) vaccine is considered safe; however, severe illness and death following vaccination have been reported.
Vaccine Safety Datalink (VSD) and US Department of Defense (DoD) data were used to identify adverse reactions following YF vaccination. Within the VSD, YF-vaccine-exposed subjects were compared to age-, site-, and gender-matched unexposed subjects. YF-vaccine-exposed DoD subjects were studied using a risk-interval design. For both cohorts, ICD-9 codes were analyzed for allergic and local reactions, mild systemic reactions, and possible visceral and neurologic adverse events (AEs).
The VSD cohort received 47,159 doses from 1991 through 2006. The DoD cohort received 1.12 million doses from 1999 through 2007. Most subjects received other vaccines simultaneously. In the VSD cohort, rates of allergic, local, and mild systemic reactions were not statistically different between YF-vaccine-exposed and -unexposed subjects. In the DoD, there was an increased risk for outpatient allergic events in the period following vaccination with YF and other vaccines rate ratios [RR 3.85, 95% confidence interval (CI) 3.35–4.41] but with no increased risk for inpatient allergic reactions. In both cohorts, inpatient ICD-9 codes for visceral events were significantly less common following vaccination; inpatient codes for neurologic events were less common in the VSD YF-vaccine-exposed adult cohort, but did not differ between exposed and unexposed periods in the DoD. In the DoD, one fatal case of YF-vaccine-associated viscerotropic disease (YF-vaccine-AVD) was detected. The estimated death rate was 0.89 for 1,000,000 YF vaccine doses (95% CI 0.12–6.31/1,000,000 doses). No YF vaccine-associated deaths occurred in the VSD.
In these closed cohorts we did not detect increased risk for visceral or neurologic events following YF vaccination. The death rate following YF vaccine was consistent with previous reports. These data support current recommendations for use of YF vaccine in young healthy individuals. These data are inadequate to judge safety of YF vaccines in elderly patients.
Yellow fever (YF) is endemic to sub-Saharan Africa and tropical regions of South America. Infections can result in hemorrhagic complications, organ failure, and death. Treatment is limited to supportive care. Thus for populations at risk, including civilian travelers and military personnel, prevention through vaccination is essential. The live attenuated YF vaccine was introduced in 1937 in the United States and was considered safe and effective.
Since 2001, the Centers for Disease Control and Prevention (CDC) have received multiple reports of death and life-threatening disease following vaccination.
Understanding of YF vaccine safety is based on clinical trials, case reports, and passive and active surveillance. No serious adverse events (AEs) or deaths have occurred in recent trials involving several thousand subjects.[2, 3]
The CDC Yellow Fever Vaccine Working Group (YFVSWG) has defined two distinct post-vaccination syndromes. YF-vaccine-associated neurologic disease (YF-vaccine-AND) manifests as several distinct clinical syndromes, including meningoencephalitis, Guillain–Barré syndrome, or acute disseminated encephalomyelitis. Depending on the specific syndrome, YF-vaccine-AND results from either direct viral invasion of the central nervous system or autoimmune mechanisms directed at the central or peripheral nervous systems. YF-vaccine-associated viscerotropic disease (YF-vaccine-AVD) results from widespread dissemination of the vaccine virus. It frequently progresses to multiorgan failure. Nearly two thirds of patients with confirmed YF-vaccine-AVD failed to survive. From 1990 to the present there have been 31 cases and 12 deaths from YF-vaccine-AVD reported in international travelers. More recently, an updated case definition of vaccine-AVD has been published by the Brighton Collaboration.
Considerable questions regarding the use of YF vaccine remain,[6-14] especially for travelers to destinations with low YF activity, where the risk of disease following vaccination may be comparable to the risk of contracting the disease while traveling. The goal of this study was to use automated claims data from the Vaccine Safety Datalink (VSD) and the US Department of Defense (DoD) to estimate risks for medical visits following allergic or local reactions and mild systemic reactions and to evaluate the rate of hospitalizations due to medical conditions that have been associated with YF-vaccine-ADV and -AND.
First, using data from the VSD in a retrospective matched cohort study design, we compared rates of ICD-9 codes for AEs between YF-vaccine-exposed and YF-vaccine-unexposed subjects. The VSD cohort included pediatric (0–17 years) and adult (≥18 years) members from eight medical care organizations (MCOs) that collaborate with the CDC on the VSD. The VSD uses linked administrative data on demographics, enrolment, immunizations, mortality, and ICD-9 and CPT codes assigned to inpatient and outpatient encounters for more than 9 million members.
The source population included all subjects enrolled in the participating MCOs from January 1, 1991 through December 31, 2006 (dates varied slightly at some sites). YF-vaccine-exposed subjects were compared with randomly selected YF-vaccine-unexposed controls, matched 1 : 3 on MCO, gender, and birth year. Unexposed subjects were assigned an index date equal to the vaccination date of their match. Unexposed subjects were not required to have a visit during the period of observation. All subjects had to be continuously enrolled in the MCO starting at least 35 days before receiving YF vaccine (or index date) through 45 days after vaccination. Only first YF vaccine doses were studied. Other vaccines administered within 3 days of YF vaccination (or index date) were recorded.
Second, we used data from the DoD to conduct a risk-interval design analysis. The population included all YF-vaccine-exposed military personnel from January 1, 1999 through December 31, 2007. Each person contributed both exposed and unexposed time. YF vaccine is recommended for active-duty personnel deployed to or traveling through YF-endemic regions and is usually administered with multiple other pre-deployment vaccines. Data on other vaccines administered were not available for this cohort. Only first doses of YF vaccine were studied.
This study was approved by the Institutional Review Boards for all VSD sites and the DoD.
For both the VSD and DoD cohorts, ICD-9 codes for identifying allergic and local AEs were selected as outcomes based on review of prior vaccine safety studies.[19-22] Additional ICD-9 codes for symptoms and conditions that could be consistent with YF-vaccine-AVD and YF-vaccine-AND were selected in consultation with the CDC YFVSWG. As laboratory and radiology data were not available to confirm whether visceral or neurologic events met formal CDC YFVSWG or Brighton case definitions, outcomes in this study are referred to as “visceral events” and “neurologic events.” In addition, for the VSD cohorts, ICD-9 codes signifying a mild systemic reaction occurring at outpatient visits were evaluated.
For all cohorts, allergic and local reactions included both inpatient and outpatient visits. “Visceral events” and “neurologic events” were limited to inpatient hospitalizations.
A large number of diagnosis codes were used to capture as many events as possible (Table 1). This table also shows the number of diagnoses for each condition in the exposed VSD cohorts. In the VSD cohorts, as the ICD-9 code 995.2 “unspecified adverse event of drug” was non-specific, we further classified these events as allergic, or local or mild systemic reactions based on chart reviews; the numbers in Table 1 reflect these events.
|Sign or symptom categories||ICD-9 CM codes||N (%)||N (%)|
|Allergic 0–3 days (inpatient/outpatient)||1 (100)||4 (100)|
|Allergic and local reactions||995.0, 995.1, 995.2,a 999.4, 999.5||1 (100)||4 (100)|
|Mild systemic reactions 1–10 days (outpatient)||29 (100)†||102 (100)†|
|Fever||780.6||10 (33.3)||7 (6.3)|
|Nausea and vomiting||787.0, 787.01–787.03||4 (13.3)||10 (9.0)|
|Lethargy||780.79||2 (6.7)||6 (5.4)|
|Headache||307.8, 784.0, 346.2||1(3.3)||32 (28.8)|
|Myalgia||729||6 (20)||28 (25.2)|
|Other joint issues||719||—||2 (1.8)|
|Syncope||780.09, 780.2||1 (3.3)||6 (5.4)|
|Other systemic reaction||995.2a||5 (16.7)||10 (9.0)|
|Visceral events 0–16 days (inpatient)||1 (100)||3 (100)|
|Liver disease||070, 570, 572, 573, 782.4, 790||—||—|
|Coagulopathy||286, 287, 459||1 (100)||—|
|Cardiac disease||359, 422.9, 427||—||1 (33.3)|
|Hypotension||458, 785||—||1 (33.3)|
|Lung disease||518, 786||—||1 (33.3)|
|Renal disease||581, 583, 584, 586, 588||—||—|
|Arthritis-arthropathy||711, 714, 716, 791||—||—|
|Neurologic events 0–36 days (inpatient)||—||6 (100)|
|Meningitis and encephalitis||047, 049, 063, 136, 232, 321, 323||—||1 (14.3)|
|CNS demyelinating disease||340, 341, 336||—||1 (14.3)|
|Hemiplegia and hemiparesis||342||—||—|
|Seizures and movement disorders||345, 780.3, 781, 780.39||—||1 (14.3)|
|Peripheral and cranial neuropathy||350–352,356, 357, 377, 378, 388||—||2 (28.6)|
|Altered mental status||310, 780.0–780.2||—||2 (28.6)|
In the VSD cohort, we also audited charts for fatalities among YF-vaccine-exposed subjects with one or more of the ICD-9 codes in Table 1 to determine whether the vaccine may have contributed to the cause of death. Chart audits could not be performed in the DoD cohort. However, a case report of the single death following YF vaccine in this population has been published.
For both cohorts, risk windows were based on CDC YFVSWG definitions and the expected time course for vaccine-related AEs. However, these windows were extended to allow lags between onset of symptoms and receipt of medical care. In the VSD, allergic or local reactions occurring during outpatient visits or inpatient hospitalizations were evaluated 0 to 3 days post-vaccination, whereas in the DoD, the risk window for allergic events was 0 to 8 days post-vaccination. For both cohorts, we used a risk window for visceral of 0 to 16 days and for neurologic, 0 to 36 days post-vaccination or matched index date. In addition, in the VSD cohort, we also searched for outpatient codes consistent with mild systemic reactions at 1 to 10 days following YF vaccine or index date.
In the DoD cohort, rates of AEs following YF vaccine within the windows described above were compared with a post-vaccination control period 48 to 120 days after vaccination. Rates of AEs are expressed as rates per 100,000 doses administered, with time windows in the control period adjusted to match the varying exposed periods.
In both cohorts, we calculated the rates for allergic or local reactions, and visceral and neurologic events among YF-vaccine-exposed and YF-vaccine-unexposed subjects. Rates for mild systemic reactions following YF vaccine in the VSD were also calculated. All contrasts were analyzed with a two-sided test with significance defined as p <0.05. For the VSD cohort, we estimated odds ratios (OR) by comparing event rates in YF-vaccine-exposed versus unexposed age-, site-, and gender-matched cohorts using conditional logistic regression via the Cox regression likelihood. The data analysis for this article was generated using sas/stat software, Version 9.13, of the sas System for Windows (SAS Institute Inc.). In the VSD, separate analyses were conducted for pediatric population (<18 years) and adults (≥18 years). For the DoD population, we obtained aggregate data, stratified by age group and by site of care (inpatient vs. outpatient events). Data were analyzed using a Poisson regression model and rate ratios (RR) of exposed windows versus unexposed are reported with 95% confidence interval (CI).
The VSD pediatric cohort had a mean age of 10.2 ± 5.5 years and received 9,604 YF vaccine doses (Table 2). The VSD adult cohort had a mean age of 46.1 ± 16.3 years and received 37,555 YF vaccine doses. Sixteen percent of adult VSD vaccinations were in subjects aged 60 to 69, and 8% were given to subjects aged 70 or older. Seventy percent of YF-vaccine-exposed pediatric subjects and 85% of YF-vaccine-exposed adult subjects received another vaccine at the same visit as YF. In the VSD pediatric cohort this most commonly included typhoid vaccine, meningococcal polysaccharide vaccine (MPSV4), and hepatitis A vaccine. The mean number of vaccines administered simultaneously (including YF-vaccine) was 3.19. In the VSD adult cohort, this also included tetanus diphtheria toxoids and inactivated polio vaccine, and the mean number of vaccines was 3.35. In contrast, only 1% of unexposed pediatric or adult subjects were vaccinated within 3 days of the index date.
|Number of subjects||9,604||37,555||1,124,730|
|Mean age ± SD||10.2 ± 5.5||46.1 ± 16.3||n/aa|
|Adult||Number (%)||Number (%)|
|18||555 (1.5)||211,791 (18.8)|
|19–29||7,229 (19.3)||687,477 (61.1)|
|30–39||6,061 (16.1)||179,361 (15.9)|
|40–49||6,904 (18.4)||43,317 (3.9)|
|50–59||7,938 (21.1)||2,717 (0.2)|
|60–69||5,955 (15.9)||67 (0.0)|
|70+||2,913 (7.8)||0 (0.0)|
|Female||4,985 (52.0)||20,230 (53.9)||n/aa|
More than 1.12 million YF vaccines were given to military personnel during the study (Table 2). Over 95% of the military cohort was between 18 and 39 years.
In VSD pediatric and adult cohorts, there were no inpatient allergic or local reactions, and no subjects had presumed anaphylaxis (ICD-9 code 995.0 or 999.4). In the adult cohort, outpatient allergic or local reactions occurred at a higher rate in vaccinated subjects, but did not reach statistical significance, RR = 4.0 (0.90–17.87) (Table 3).
|Signs and symptoms||Events (rate per 100,000 doses)||OR (95% CI), p|
|Allergic and local reactionsa||0||1 (10.4)||—|
|Mild systemic reactions†||60 (209.4)||29 (302.0)||1.44 (0.93–2.25), 0.10|
|Visceral ‡||1 (3.5)||1 (10.4)||3.0 (0.19–48.0), 0.44|
|Neurologic §||2 (7.0)||0||—|
|Allergic and local reactionsa||3 (2.7)||4 (10.7)||4.0 (0.90–17.87), 0.07|
|Mild systemic reactions†||348 (310.3)||102 (271.6)||0.87 (0.70–1.09), 0.22|
|Visceral||35 (31.2)||3 (8.0)||0.26 (0.17–0.95), 0.02|
|Neurologic§||44 (39.2)||6 (16.0)||0.41 (0.17–0.95), 0.04|
|Death||16 (14.3)||5 (13.3)||0.94 (0.34–2.56), 0.90|
In the DoD, there was an excess of outpatient allergic events, RR = 3.85 (3.35–4.41). However, there was no increased risk for inpatient allergic events. There were only four inpatient allergic events in the exposed period in the entire cohort (0.37/100,000 doses). Further details were not available to determine whether any of these represented true cases of anaphylaxis (Table 4).
|Events (rate per 100,000 doses)|
|Exposed period||Unexposed period||Rate ratio (95% CI), p|
|Outpatient||290 (26.6)||695 (6.9)||3.85 (3.35–4.41), <0.0001|
|Inpatient||4 (0.37)||19 (0.19)||1.94 (0.66–5.7), 0.23|
|Inpatient||64 (5.8)||401 (8.0)||0.73 (0.56–0.94), 0.02|
|Inpatient||179 (16.0)||356 (15.9)||1.01 (0.84–1.21), 0.94|
For VSD pediatric and adult cohorts, there was no significant increase in medically attended mild systemic reactions within 10 days of vaccination (Table 3).
Visceral events were rare following YF vaccination. In the VSD pediatric cohort, there was only a single inpatient visceral ICD-9 code occurring within 16 days of vaccination (10/100,000 doses); while in the VSD adult cohort only three occurred (8/100,000 doses) (Table 3). In both the VSD adult and DoD cohorts, visceral events resulting in a hospitalization were significantly less common in YF-vaccine-exposed adults.
Neurologic inpatient events following YF vaccine occurred infrequently. There were no events in the VSD pediatric cohort and only six inpatient neurologic events occurred within 36 days of vaccination in the VSD adult cohort (16/100,000 doses) (Table 3). There was a decreased risk for neurologic events in the VSD adult cohort. In the DoD cohort, risks for neurologic events did not differ between YF-vaccine exposed and unexposed periods.
No deaths occurred in the VSD pediatric population. In the VSD adult population, no difference in mortality rates was observed between exposed (5 deaths) and unexposed (16 deaths) (OR 0.94, 0.34–2.56). Only one of the five deaths in the VSD YF-vaccine-exposed adults had an inpatient code possibly related to a visceral event. After chart review, the case was judged not to be related to YF vaccine. In the DoD population, one death occurred that was due to confirmed YF-vaccine-AVD. The point estimate of the death rate for the DoD population was 0.89 for 1,000,000 YF vaccine doses (95% CI 0.12–6.31/1 million doses).
This study examined safety of more than 1 million doses of YF vaccine in two large, closed cohorts. The events studied consisted of ICD-9 codes for signs and symptoms of allergic or local reactions, and minor systemic reactions, and inpatient ICD-9 codes representing neurologic or visceral events. Rates for outpatient allergic events were increased after vaccination in the DoD with an odds ratio approaching 4. In the VSD adult cohort, the point estimate was similar, but not significant due to small numbers. All the other outcome events including those leading to hospitalization were not increased in YF-vaccine-exposed subjects.
In these closed cohorts, only one death was directly attributable to YF vaccine. The point estimate risk for death was 0.89 per million, which is consistent with the rates reported by Struchiner et al. using Brazilian surveillance data.
Compared to the unexposed, the lower rate of hospitalization for visceral and neurologic events among YF-vaccine-exposed VSD adults was likely due to the “healthy traveler” effect. Similarly, compared to unexposed post-vaccination periods, the lower rate for visceral events immediately following vaccination in the DoD cohort was likely due to the “healthy warrior” effect. That is, only healthy persons travel internationally or get deployed in the military. Because of this inherent bias, no attributable risk could be calculated.
Previous studies of YF vaccine safety in US populations have relied on reports to the Vaccine Adverse Event Reporting System (VAERS). These studies estimated the rates of YF-vaccine-AND to be 0.4 to 0.8/100,000 doses and the rates of YF-vaccine-AVD to be 0.3 to 0.4/100,000 doses.[13, 14] Kitchener reported a rate of 1.3 per million for both YF-vaccine-AVD and -AND based on European surveillance data. More recently, using active surveillance from Brazil, Martins et al. reported state-specific rates of YF-vaccine-AVD of 0.31/100,000 YF vaccine doses in Sao Paulo state and 0.11/100,000 doses in Rio Grande do Sul state. The intensity of active surveillance varied from state to state. Recently, Thomas[26, 27] has summarized many of these studies.
This study was unable to answer two important public health questions. First, it was underpowered to assess the risk of death following YF vaccine. Second, analyses of data from passive reports to VAERS have suggested that advanced age was a risk factor for severe disease and death in these cases.[28-31] Other studies have suggested that advanced age is a risk for serious AEs. Owing to inadequate numbers of elderly subjects in both cohorts, we were underpowered to determine whether AEs were more common with increased age.
This study has several other limitations. First, in both cohorts, diagnostic codes for symptoms and signs of neurologic and visceral events have unknown sensitivity and specificity for identifying reactions to YF vaccine. Thus, our results represent an estimate of rates of medically attended events for symptoms and signs that appear in the CDC YFVSWG case definitions, not diagnoses of either YF-vaccine-AVD or YF-vaccine-AND. Second, in the DoD population, only aggregate electronic data were available. Codes representing hypersensitivity reactions could not be confirmed by chart review, and data on egg allergy for patients experiencing reactions was not available. Third, most subjects in both cohorts received multiple other vaccines simultaneously with YF vaccine. Thus, we were unable to assess whether any of the outcomes were due to YF vaccine or other vaccines.
This study provides a useful description of events following YF vaccine administration in the context of standard travel and military vaccination protocols in the United States. Our findings may not be generalizable to YF vaccine in other settings. The rates of AEs may be lower in national and regional YF vaccine campaigns when it is administered as a single vaccine.
This was the largest-ever study of the safety of the YF vaccine in the United States. Severe AEs resulting in hospitalization did not differ between the vaccinated and unvaccinated. In this closed population, only one death occurred, consistent with death rates obtained from other studies. These data are inadequate to judge safety in elderly patients, but they support current CDC recommendations for judicious use of YF vaccine in young healthy individuals.
This work was supported by a subcontract with America's Health Insurance Plans (AHIP) under contract 200-2002-00732 from the Centers for Disease Control and Prevention (CDC).
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
The authors state they have no conflicts of interest.